Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 10.12
+1.10 (12.20%)
Nov 6, 2026, 4:00 PM EST
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year. That makes Satellos Bioscience the 38,308th largest employer in the world and 670th in Canada.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-2.46M CAD
Market Cap
214.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Eupraxia Pharmaceuticals | 49 |
| Bright Minds Biosciences | 26 |
| BriaCell Therapeutics | 16 |
| Medicenna Therapeutics | 15 |
| Sernova Biotherapeutics | 8 |
| Helix BioPharma | 7 |
Satellos Bioscience News
- 13 hours ago - Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results - MarketBeat
- 23 hours ago - Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027 - Nasdaq
- 1 day ago - Satellos Bioscience Transcript: Study update - Transcripts
- 1 day ago - Satellos Bioscience Press release: Study update - Filings
- 1 day ago - Satellos Bioscience Slides: Study update - Filings
- 1 day ago - Satellos changes primary endpoint in BASECAMP trial after FDA feedback - TheFly
- 1 day ago - Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback - GlobeNewsWire
- 1 day ago - Satellos Bioscience Slides: Corporate presentation - Filings